Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance versus continuation of first-line chemotherapy in advanced gastric or gastroesophageal junction adenocarcinoma
2015-003300-23Phase 3Unknown
- Sponsor
- Merck KGaA
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Merck KGaA. Primary endpoints: Overall survival and Progression-free survival. Status: unknown.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2015-003300-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003300-23.